Zure produktuak, zerbitzuak edo biak beste enpresa batengandik bereizi nahi badituzu, baliteke marka edo izen komertzial bat behar izatea. Ezagutu zer diren, zer den erregistratzeko prozedura eta zer dakarren.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Arazo tekniko bat konpontzen duen edo abantaila praktiko bat duen gailu, produktu edo prozedura berri bat baduzu, hura babesteko hainbat modu daude Espainian eta beste herrialde batzuetan. Ikusi nola egin.
Zure berrikuntza zure produktuaren estetikan, apainduran edo itxuran datza? Babestu diseinu industrial baten bidez. Jakin ezazu zer eskubide ematen dituen erregistroak eta nola egin izapideak.
Mundu osoan argitaratutako patenteak informazio zientifiko, tekniko eta komertzialaren iturri baliotsua dira.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ekintzailea edo enpresa bazara eta zure negozioaren errentagarritasuna sustatu eta hobetu nahi baduzu, zure erakundeko aktibo ukiezinak behar bezala babestuz, gune honetan aurkituko duzu behar duzuna.
158
resultados
Última actualización
19/07/2025 [07:04:00]
Resumen de: WO2025151241A1
The wireless heart telemetry device and accompanied patient monitoring system provides continuous patient monitoring in a comfortable and streamlined design for healthcare settings by providing electrocardiogram (ECG) physiological data in a wireless skin patch device. The wireless heart telemetry device integrates into a full patient monitoring system to provide additional vital physiological patient data in wireless system. This additional physiological data includes pleth, blood oxygen saturation (SPO2), blood pressure, heart rate, respiration rate, temperature, and glucose. The pulse oximeter portion of the system includes mechanical designs such as a finger clip, ring, and bracelet design for enhanced usage, accuracy, and comfort. Another example embodiment of the pulse oximeter portion of the system includes fall detection, bed alarm, and location monitoring services. An additional example embodiment includes a melanin bias reducing pulse oximeter.
Resumen de: WO2025150098A1
This non-invasive measurement device comprises: a light source unit 10 that emits excitation light; an irradiation optical system 11 that irradiates skin tissue 2 with the excitation light; a detection optical system 12 that collects Raman-scattered light from the skin tissue 2; a spectroscope 13 that separates the Raman-scattered light; and an analysis device 14 that analyzes a spectroscopic signal obtained as a result of the separation by the spectroscope so as to measure blood sugar level. The irradiation optical system 11 forms the excitation light into minute beam spots in a dot pattern and irradiates the skin tissue 2 obliquely with the excitation light.
Resumen de: US2025229018A1
A drug infusion device with integrated power supply includes a drug reservoir, used for accommodating the drug to be infused, provided with a piston and a screw; a driving wheel, connected with the screw, driving the screw to push the piston forward by rotation; a power supply, used to supply power to the infusion device, including a power supply shell, a power supply cell, electrolyte and a cover plate; and a case, including an upper case and a lower case, for accommodating the drug reservoir, the drive wheel and the power supply. The power supply shell is integrated with the lower and/or the cover plate is integrated with the upper case.
Resumen de: US2025228478A1
Disclosed are devices, systems and methods for in vivo monitoring of localized environment conditions within a patient user by measuring analytes, including glucose, oxygen, and/or other analytes. In some aspects, a sensor device includes a wafer-based substrate, at least one electrochemical sensor two-electrode contingent including a working electrode and a reference electrode on the substrate and configured to detect a target analyte in a body fluid when the sensor device is deployed within a subject's body, where the working electrode is functionalized by a chemical layer configured to facilitate a reaction involving the target analyte that produces an electrical signal; and an electronics unit in communication with the electrochemical sensor electrode contingent to transmit the electrical signal to an external processor.
Resumen de: US2025229024A1
Techniques related to temporary setpoint values are disclosed. The techniques may involve causing operation of a fluid delivery device in a closed-loop mode for automatically delivering fluid based on a difference between a first setpoint value and an analyte concentration value during operation of the fluid delivery device in the closed-loop mode. Additionally, the techniques may involve obtaining a second setpoint value. The second setpoint value may be a temporary setpoint value to be used for a period of time to regulate fluid delivery, and the second setpoint value may be greater than the first setpoint value. The techniques may further involve causing operation of the fluid delivery device for automatically reducing fluid delivery for the period of time based on the second setpoint value.
Resumen de: US2025232078A1
Examples of a simulation framework are provided to evaluate time varying systems using a piecewise linear time invariant simulation (PLIS) approach. The simulation framework can be configured for an artificial pancreas wireless network system that controls blood glucose in Type 1 Diabetes patients with time varying properties such as physiological changes associated with psychological stress and meal patterns.
Resumen de: WO2025150099A1
A non-invasive measurement device according to the present invention comprises: a light source unit 10 which emits excitation light; an irradiation optical system 11 which irradiates skin tissue 2 with the excitation light; a detection optical system 13 which collects Raman scattered light from the skin tissue 2; a spectroscope 14 which disperses the Raman scattered light; and an analysis device 15 which analyzes a spectral signal obtained as a result of the dispersion by the spectroscope 14 and measures a blood glucose level. The irradiation optical system 11 shapes the cross section of the excitation light into a ring and irradiates the skin tissue 2 with the excitation light, and the detection optical system 13 is positioned to detect light returned from a part of the skin tissue 2 that is the central portion of a ring-shaped beam spot irradiated on the skin tissue 2.
Resumen de: US2025229023A1
The invention discloses a closed-loop artificial pancreas insulin infusion control system, including: detection module, an infusion module and an electronic module, the detection module, the infusion module and the electronic module all equipped with a control unit, and each control unit is preset with a first algorithm, a second algorithm and a third algorithm correspondingly. When different priority conditions are met, different modules determine the current insulin infusion information. Therefore, the closed-loop artificial pancreas insulin infusion control system can automatically switch control units according to different situations, so as to avoid affecting the user experience and even bringing security risks to users when a module set with the control unit cannot work normally.
Resumen de: US2025230174A1
Glucose-sensing luminescent dyes, polymers, and sensors are provided. Additionally, systems including the sensors and methods of using these sensors and systems are provided.
Resumen de: US2025228501A1
Provided herein are systems and methods of predicting and managing blood glucose levels in individuals, including systems and methods of predicting blood glucose levels based on predicted future glucose factors. Also provided herein are systems and methods of recommending glucose interventions based thereon. It is appreciated by the present disclosure that it is better to prevent extreme blood glucose levels before they occur than merely detecting such levels when they occur. Accordingly, the systems and methods described herein utilized a combination of contextual information and current time glucose measurements/estimates to predict the likelihood of different scenarios that might lead to such extreme levels before they occur.
Resumen de: US2025228475A1
One embodiment is a method for implementing a cloud-based portable miniaturized system for performing non-invasive blood glucose level measurement in real time. The method includes using an optical source to emit optical radiations at certain wavelengths through breath in an air collection chamber; receiving the emitted optical transmissions at a photodetector; converting the received optical transmissions to digital data; accumulating the digital data for a first time period; and periodically transmitting the accumulated digital data to a cloud service for further processing.
Resumen de: AU2023377269A1
A method, system, and computer-readable medium are provided for an Automated Insulin Delivery (AID) system in which Model Predictive Control (MPC) thereof implements weighting of glucose target error relative to corresponding predicted blood glucose (BG) levels according to insulin on board (IOB). Accordingly, basal insulin infusion and available additional bolusing each in connection with glycemic disturbances such as unannounced meals can be proximally administered to maintain time in range (TIR) without incurring insulin stacking.
Resumen de: EP4585239A2
An insulin infusion system is provided with a manual insertion device having a dual retraction spring (230) configuration for automatic introducer needle (222) retraction. A button (200) of the insertion device is used to insert the introducer needle (222) and catheter (202), and once the introducer needle (222) and catheter (202) have been fully inserted, a rotating engagement releases the dual retraction springs (230) such that the introducer needle (222) automatically retracts, leaving the catheter (202) in the body of the user. An end of the introducer needle (222) remains in the inserted catheter (202) and/or in the septum (206) of the inserted catheter (202) to provide an uninterrupted fluid path.
Resumen de: US2025221643A1
Multiple enzymes may be present in one or more active areas of an electrochemical analyte sensor for detecting one or more different analytes. In particular, an analyte sensor may comprise a sensor tail configured for insertion into a tissue and one or more working electrodes having a glucose-responsive active area and an ethanol-responsive active area to detect glucose and ethanol in vivo.
Resumen de: US2025226076A1
An aspect of the invention provides a method and a product for determining a modification of the therapy management by using a processor unit which retrieves few data related to the blood glucose measurement performed over a predetermined time period; retrieve the medication delivery parameter executed by the delivery device over said predetermined time period; retrieve from the memory data associated to the CIR of the patient; and determine a modification to the therapy based on at least a part of the retrieved data.
Resumen de: US2025222201A1
Techniques disclosed herein relate to infusion devices and alerts. In some embodiments, the techniques may involve determining an expected glucose measurement value after delivery of a correction bolus based on an amount of the correction bolus and a current amount of active insulin in a body of a patient. The techniques may further involve obtaining a current glucose measurement value. The techniques may further involve detecting an anomalous response to the correction bolus responsive to determining that a difference between the current glucose measurement value and the expected glucose measurement value exceeds a predetermined threshold.
Resumen de: WO2025146479A1
Systems and methods for monitoring glucose levels of a user are described. Data indicative of glucose levels of the subject is received. A count is assigned for each glucose episode based at least on an area under the curve of the each glucose episode in a dataset of time- correlated glucose data. A running sum of counts for each glucose episode in a time period is calculated. The running sum of the counts may be displayed in a numerator of a fraction and a target count goal in a denominator of the fraction. A progress indicator representative of the running sum of the counts relative to a target count goal for the time period may also be displayed. A length of a variable portion may be proportional to the running sum of the counts, and a total length of the progress indicator may be proportional to the target count goal.
Resumen de: US2025221637A1
This invention provides a coin-sized, fully integrated and wearable continuous glucose monitoring system (CGMs) via combining cutting-edge technologies from the intersecting fields of biosensors, minimally invasive tools, and hydrogels. The invention includes three major parts: 1) an emerging biochemical amplifier, the organic electrochemical transistor (OECT), to improve sensitivity beyond traditional electrochemical modules; 2) a microneedle array for interstitial-fluid (ISF) sampling with reduced pain during skin penetration; and 3) a tough, adhesive enzymatic-hydrogel-membrane to enhance reliability of glucose sensing on skin. Unlike conventional CGMs, the employed OECT amplifier empowers the CGM (OECT-CGMs) with a high anti-noise ability, an on-demand-tunable sensitivity and current regeneration ability, enabling long-term stable glucose sensing within specific clinical ranges (1 ̃20 mM). This work paves the way for the development of next-generation CGMs that can simultaneously deliver high and adjustable sensitivity, minimal invasiveness, and improved wearability.
Resumen de: US2025221639A1
Systems and methods for monitoring glucose levels of a user are described. Data indicative of glucose levels of the subject is received. A count is assigned for each glucose episode based at least on an area under the curve of the each glucose episode in a dataset of time-correlated glucose data. A running sum of counts for each glucose episode in a time period is calculated. The running sum of the counts may be displayed in a numerator of a fraction and a target count goal in a denominator of the fraction. A progress indicator representative of the running sum of the counts relative to a target count goal for the time period may also be displayed. A length of a variable portion may be proportional to the running sum of the counts, and a total length of the progress indicator may be proportional to the target count goal.
Resumen de: US2025221673A1
Systems and methods for predictive glucose in accordance with embodiments of the invention are illustrated. One embodiment includes glucose management device, including a brain signal recorder, and a controller, including a processor, and a memory, the memory containing a glucose monitoring application configured to direct the processor to record a brain activity signal of a user's brain using the brain signal recorder, and decode the brain activity signal to predict future glucose levels of the patient.
Resumen de: WO2025147163A1
The present disclosure relates to an artificial intelligence-based apparatus and method for pancreatic frozen section examination and diagnosis. The apparatus comprises: a memory; and a processor including an artificial intelligence engine for the pancreatic frozen section examination and diagnosis, wherein the processor can acquire a first frozen section image of the pancreas, acquire a second frozen section image corresponding to the first frozen section image of the pancreas, and generate and provide a diagnosis result for the pancreatic frozen section examination on the basis of the first frozen section image and the second frozen section image by using the artificial intelligence engine.
Resumen de: US2025221674A1
Systems and methods for monitoring glucose variability in a subject are described. Data indicative of glucose levels of the subject is received from a sensor control device. A first glucose variability metric of the subject in a first time period is determined. The first glucose variability metric may be compared to a threshold. A first indicator is displayed if the first glucose variability metric does not exceed the threshold and a second indicator is displayed if the first glucose variability metric exceeds the threshold. Additional glucose variability metrics may be determined for subsequent time periods according to a rolling window, and the indicators may be displayed real time or in a report. The glucose variability metric may be a measure of variability compared to a baseline, a difference between a maximum and minimum glucose level, or time in or out of a target range.
Resumen de: CN119731745A
Systems and methods for determining a glucose value of a user are disclosed herein. The method includes: receiving a plurality of data inputs associated with biometric data of a user, the plurality of data inputs including at least one data input representing past estimated glucose values of the user; and processing the plurality of data inputs with a multi-head temporal convolutional neural network to generate a blood glucose value for the user. The method further includes providing a notification to the user based at least in part on the blood glucose value.
Resumen de: US2025213145A1
A method for non-invasively estimating blood glucose for estimating a blood glucose value of a user by a computing device. The method includes receiving a plurality of electrocardiogram (ECG) waveforms of the user, extracting at least two first ECG features from each of the plurality of ECG waveforms of the user, respectively determining a first feature peak position corresponding to each of the first ECG features, calculating at least one peak distance between the plurality of the first feature peak positions, and estimating the blood glucose value of the user based on the peak distance. The first ECG features are selected from the group consisting of a P-wave, a Q-wave, an R-wave, an S-wave, a T-wave, and a U-wave. Furthermore, a computing device for non-invasively estimating blood glucose, a device for non-invasively measuring ECG signal, and a non-transitory computer readable storage medium are utilized for the method.
Nº publicación: WO2025140661A1 03/07/2025
Solicitante:
HUAWEI TECH CO LTD [CN]
\u534E\u4E3A\u6280\u672F\u6709\u9650\u516C\u53F8
Resumen de: WO2025140661A1
A blood glucose management method, a user interface, and a related apparatus. The blood glucose management method comprises: on the basis of historical blood glucose levels of a user, determining a first mealtime; on the basis of one or more of a mealtime inputted by the user, and body movements and the heart rate of the user, determining a second mealtime; on the basis of the first mealtime and the second mealtime, determining a third mealtime; and assessing a blood glucose health status of the user by means of the third mealtime. Historical mealtimes of a user that are determined using multiple methods are combined to predict a mealtime of the user, so that an electronic device can more accurately assess a blood glucose situation of the user.
BOPI
Sede Electrónica
